|
The FDA is going to monitor pharmaceuticals made in Japan — as well as food products — for any signs of elevated radiation levels, a spokeswoman for the agency tells us.
|
|
The generic-drug maker Mylan has sued the FDA in a bid to allow the introduction of copycat versions of Pfizer's popular cholesterol-lowering drug Lipitor in June, five months earlier than expected.
|
|
The prices of multiple sclerosis medicines have risen as much as 39 percent since last year, even as competition intensified with the introduction of the first pill to treat the disease.
|
|
A potential therapy for diabetes being developed by the biotech company Xoma in partnership with the French pharma firm Servier failed to meet the primary endpoint in a phase IIb study.
|
|
Just three months after the FDA rejected the new Brilinta bloodthinner from AstraZeneca, France is now reportedly giving the drugmaker a hard time as well. Even though the European Medicines Agency already endorsed the treatment, the HAS health technology assessment agency in France has decided the med has an unfavorable risk/benefit profile, which puts a halt to final pricing talks and a product launch, according to an investor note from Sanford Bernstein analyst Tim Anderson.
|
|
Researchers at Weill Cornell Medical College and the University of Notre Dame said they used drugs being tested for cancer to correct a cholesterol-storage defect in a lethal, rare disease called Niemann-Pick Type C (NPC).
|
|
Bristol-Myers Squibb Co. gave incoming Chief Executive Lamberto Andreotti a 42 percent raise in 2010 as he carried on company efforts to reposition itself as a specialty biopharmaceutical maker.
|
|
Big U.S. and European pharmaceutical companies face some short-term economic disruption from the earthquake disaster. But Leerink Swann analyst Seamus Fernandez assures that it should “be muted relative to other industries.”
|
|
Pfizer Inc. (PFE) investors are pushing for a spinoff of the drugmaker’s nutrition business that would command a price tag of $6.8 billion and deliver more than twice the gains of the U.S. stock market.
|
|
Epistem has entered into a three-year collaboration with Sanofi-aventis U.S., Inc. for the use of Epistem’s biomarker gene expression profiling and immunohistochemistry technologies. Epistem will provide discovery through to clinical biomarker support for Sanofi’s oncology programs. Epistem may receive as much as $4 million in research support payments including certain cost reimbursement.
|
News
